Copenhagen-based Adcendo is paying what is rumoured to be tens of millions of dollars in upfront fees for rights to Multitude's anti-tissue factor (TF) ADC AMT-754 – now renamed ADCE-T02 ...
Some results have been hidden because they may be inaccessible to you